

COMPLETE IF KNOWN

(use as many sheets as necessary)

Sheet

1

of

3

Application Number

10/526,178

Filing Date

February 28, 2005

First Named Inventor

Raman K. Bakshi et al.

Group Art Unit

Examiner Name

Attorney Docket Number

21140YP

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number Kind Code (if known)		
VB			WO 99/64002	Merck & Co., Inc.	12/16/1999
			WO 01/91752	Merck & Co., Inc.	12/06/2001
			WO 01/70708	Merck & Co., Inc.	09/27/2001
			WO 01/70337	Merck & Co., Inc.	09/27/2001
			WO 00/74649	Merck & Co., Inc.	12/14/2000
			WO 96/35713	Pfizer, Inc.	11/14/1996
			WO 03/009847	Amgen, Inc.	02/06/2003
			WO 02/068387	Merck & Co., Inc.	09/06/2002
			WO 02/070511	Bristol-Myers Squibb Company	09/12/2002
VB			WO 96/38471	Pfizer, Inc.	12/05/1996

1. Balasubramanian

Date Considered

6/24/07

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/526,178
Filing Date	February 28, 2005
First Named Inventor	Raman K. Bakshi et al.
Group Art Unit	
Examiner Name	

Sheet	2	of	3	Attorney Docket Number	21140YP
-------	---	----	---	------------------------	---------

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
VB			WO 02/15909		Merck & Co., Inc.	02/28/2002
			WO 02/059095		Eli Lilly and Company	08/01/2002
			WO 02/059107		Eli Lilly and Company	08/01/2002
			WO 02/059108		Eli Lilly and Company	08/01/2002
			WO 02/059117		Eli Lilly and Company	08/01/2002
			WO 02/068388		Merck & Co., Inc.	09/06/2002
			WO 03/007949		Merck & Co., Inc.	01/30/2003
			WO 03/031410		Neurocrine Biosciences, Inc.	04/17/2003
			WO 01/58891		Vertex Pharmaceuticals Incorporated	08/16/2001
VB			WO 99/09984		Merck & Co., Inc.	03/04/1999

**Examiner
Signature**

1/ Balasubramanian

Date Considered

6/24/07

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/526,178
Filing Date	February 28, 2005
First Named Inventor	Raman K. Bakshi et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	21140YP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
VB	AA	Wessells et al., J. of Urology, Vol. 160(2), (1998), pp. 389-393, "Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction..."
	AB	Giraud et al., Brain Research, Vol. 809 (1998), pp. 302-306, "Feeding effects of hypothalamic injection of melanocortin 4 receptor ligands"
	AC	Chen et al., Cell, Vol. 91 (1997), pp. 789-798, "Exocrine gland dysfunction in MC5-R-deficient mice: ..."
	AD	Chaki et al., Exp. Opin. Ther. Patents (2001), Vol. 11(11), pp. 1677-1692, "Recent advances in feeding suppressing agents: Potential therapeutic strategy for the treatment of obesity"
	AE	Dorr et al., Life Sciences, Vol. 58 (1996), pp. 1777-1784, "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study"
	AF	Kask et al., Biochem. & Biophys. Res. Comm., Vol. 245 (1998), pp. 90-93, "Selective antagonist for the melanocortin 4 receptor (HS014) increases food intake in free-feeding rats"
	AG	Huszar et al., Cell, Vol. 88 (1997), pp. 131-141, "Targeted disruption of the melanocortin-4 receptor results in obesity in mice"
	AH	Wikberg et al., Pharma., Vol. 42 (2000), pp. 393-420, "New aspects on the melanocortins and their receptors"
	AI	Wikberg et al., Exp. Op. Ther. Patents, Vol. 11 (2001), pp. 61-76, "Melanocortin receptors: New opportunities in drug discovery"
	AJ	Andersson, Exp. Op. Ther. Patents, Vol. 11 (2001), pp. 1583-1592, "Ligands to the melanocortin receptors"
	AK	Peptides: Frontiers of Peptide Science, Fifteenth American Peptide Symposium, June 14-19, 1997 (Nashville, TN)
	AL	Corcos et al., Society for Neuroscience, Vol. 23 (1997), Abstract 267.9, "HP 228 is a potent agonist of melanocortin receptor 4, and significantly attenuates obesity and diabetes in Zucker fatty rats"
VB	AM	Marsh, Nat. Genet., Vol. 21 (1999), pp. 119-122, "Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides"

Examiner Signature

VB. Schenck

Date Considered

6/24/07

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449A/PTO

INFORMATION ~~DISCLOSURE~~

STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/526,178
---------------------------	-------------------

Filing Date	February 28, 2005
--------------------	-------------------

First Named Inventor	R.K. Bakshi et al.
-----------------------------	---------------------------

Group Art Unit	1642
----------------	------

Examiner Name

Sheet	1	of	2
-------	---	----	---

Attorney Docket Number	21140YP
------------------------	---------

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

6/24/07

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number 10/526,178

Filing Date February 28, 2005

First Named Inventor R.K. Bakshi et al.

Group Art Unit 1642

Examiner Name

Attorney Docket Number 21140YP

Sheet

2

of

2

NON PATENT LITERATURE DOCUMENTS

Examiner
Initials*

Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

Examiner
Signature

V. Balasubramaniam

Date
Considered

6/24/07

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005